>>Home>>Contemporary issuesCurrent messages from the companies

With a unique value proposition in the drug development and diagnostic markets, Chimera's innovative Imperacer® products and services have experienced widespread market acceptance.
“Imperacer® has a proven record for quantifying low-abundant proteins, peptides, biomarkers and a range of “difficult to quantify” markers”, says Mark Spengler, Product Manager at Chimera Biotec. “Among others Imperacer® is currently being used in fields like Alzheimer’s, rheumatoid arthritis, cardiovascular and cancer.”
© 2013 TechnologieZentrumDortmund GmbH - Emil-Figge-Straße 76-80 - 44227 Dortmund